B. Braun has announced that through their collaboration Schreiner MediPharm, they are launching the first FDA-approved prefilled heparin syringe with an integrated needle protection device.
Safety devices on syringes are implemented to reduce the risk of needlestick injuries to healthcare staff. When B. Braun Medical sought an efficient and safe needle protection system for its prefilled Heparin Sodium Injection for the U.S. market, they found Schreiner MediPharm’s label-integrated Needle-Trap system.
The Needle-Trap system is an internationally established system that complies with the U.S. NIOSH requirements for safe instruments and has been awarded 510(k) Pre-Market Notification by the FDA for marketing in the U.S.
Gene Dul, President of Schreiner MediPharm U.S, explains, “Clinical staff benefit from reliable protection against needlestick injuries because Needle-Trap’s activation is easy and irreversible. It is intuitive to use and requires no change in injection technique.”
Schreiner reports that its Needle-Trap is the only label-based needle protection system on the market. The plastic needle trap is an integral component of the marking label and serves to secure the needle after the injection has been performed. Due to its special construction, Needle-Trap can easily and cost-efficiently be integrated into existing pharmaceutical production processes. Requiring only minor modifications of the application systems, no changes must be made to secondary packaging, and minimal space during shipping, storage and disposal are needed.
“Our products are designed to increase patient and clinician safety, while reducing medication errors and improving dosage accuracy and workflows. Obviously, efficient and economical manufacturing are equally important. Collaborating with Schreiner MediPharm allowed us to meet those needs,” says Leigh Nickens, Director of Marketing, Fluid Therapy and Injectable Drugs at B. Braun.
